Total operating expenses for the quarter were $21.0 million, compared to $14.2 million in the same period in 2022. The increase in operating expenses is primarily attributable to an increase of $5.1 million in sales and marketing costs. The increase in sales and marketing costs is a result of the expansion of our commercial organization in preparation of the commercial launch of full-thickness skin defects that happened in the second quarter. In addition, the increase in operating expenses included an increase of $0.6 million in R&D costs, and an increase of $1.1 million in G&A costs, primarily due to an increase in stock compensation expense.
tell me why, page-9
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.63 |
Change
0.160(6.48%) |
Mkt cap ! $179.0M | |||
| Open | High | Low | Value | Volume |
| $2.54 | $2.64 | $2.54 | $874.2K | 336.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3056 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.63 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |